Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder Academic Article uri icon

Overview

MeSH Major

  • Criminals
  • Naltrexone
  • Narcotic Antagonists
  • Opioid-Related Disorders

abstract

  • While extended-release naltrexone appears to be effective in increasing both quality-adjusted life-years (QALYs) and abstinence, it does not appear to be cost-effective using generally accepted value thresholds for QALYs, due to the high price of the injection.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5503784

Digital Object Identifier (DOI)

  • 10.1111/add.13807

PubMed ID

  • 28239984

Additional Document Info

start page

  • 1440

end page

  • 1450